The α-D-glucan from marine fungus Phoma herbarum YS4108 ameliorated mice colitis by repairing mucosal barrier and maintaining intestinal homeostasis.

Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology with increasing incidence world widely. Previous studies have indicated that the α-D-glucan YCP purified from the mycelium of the marine fungus Phoma herbarum YS4108 had certain immunomodulatory activities in animal and cell models. In the study, the therapeutic effect and intestinal regulatory activity of YCP (40 mg/kg, intraperitoneal injection) on UC were investigated in dextran sulfate sodium (DSS)-induced colitis mice. The results showed YCP could improve the general symptoms, reestablish the intestinal immune balance, and repair the mucosal barrier in colitis mice. The administration of YCP also significantly increased butyrate and isovaleric acid levels. In addition, YCP resulted in prominent alterations on specific microbiota including Firmicutes, Bacteroidetes, Proteobacteria, Clostridiales, and Lachnospiraceae which are closely related to immune regulation and mucus repair. Therefore, YCP may be a candidate for curing UC because of its conspicuous effects comparable to 5-aminosalicylic acid (5-ASA).